Compass Therapeutics Files 8-K
Ticker: CMPX · Form: 8-K · Filed: Apr 1, 2025 · CIK: 1738021
| Field | Detail |
|---|---|
| Company | Compass Therapeutics, Inc. (CMPX) |
| Form Type | 8-K |
| Filed Date | Apr 1, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, sec-filing, reporting
TL;DR
Compass Therapeutics filed a standard 8-K on 4/1/25, no major news.
AI Summary
Compass Therapeutics, Inc. filed an 8-K on April 1, 2025, to report on other events and financial statements. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This 8-K filing indicates routine corporate reporting by Compass Therapeutics, Inc. to the SEC, without disclosing specific material events or financial updates.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not contain any new material information that would indicate increased risk.
Key Players & Entities
- Compass Therapeutics, Inc. (company) — Registrant
- April 1, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-39696 (identifier) — Commission File Number
- 80 Guest Street, Suite 601 (address) — Principal Executive Offices
- Boston, Massachusetts (location) — Principal Executive Offices City and State
- 02135 (zip_code) — Principal Executive Offices Zip Code
- 617-500-8099 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits as of April 1, 2025.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is April 1, 2025.
In which state is Compass Therapeutics, Inc. incorporated?
Compass Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address of Compass Therapeutics, Inc.?
The principal executive office address is 80 Guest Street, Suite 601, Boston, Massachusetts 02135.
Does this filing disclose any specific new material events or financial results?
Based on the provided text, this filing appears to be a routine 8-K reporting on standard categories and does not explicitly disclose specific new material events or financial results.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 1, 2025 regarding Compass Therapeutics, Inc. (CMPX).